Accessible version: https://youtu.be/Z80AgLojsy0
•
Persistent infection with high-risk types required for progression to precancer and cancer Peak incidence of precancers in late 20’s and of cancers in mid to late 40’s
Average Number of New HPV-associated Cancers Overall, and by Sex, in the United States, 2005-2009 n=1003 n=3039 n=694 n=2317 n=1003 n=694 n=3039 n=1687 n=3084 Oropharynx n=9312 n=11279 n=4771 * In addition: Cervical disease and pre-invasive cancers: CIN1,2,3~ 1.4 million; AIN3~4300; VIN3~27,000,VAIN3~7600 (CDC, unpublished data)
Y axis scale is different for cervical cancer.
Males Oropharynx Anus Females * 3.9 * 2.6 White White * 1.7 3.7 * * * -1.6 5.6 Black Black * -0.3 2.5 1.0 2.1 API API -2.5 1.6 4.9 AI/AN AI/AN 0.8 0.9 Hispanic Hispanic 0.2 0.7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9
HPV attributable cancers = 26,000 cancers HPV 16/18 attributable cancers= 21,000 cancers
2006 2007 2008 2009 2010 2011 2012 October June October
Vaccine first introduced in Australia in 2006 (dashed line) 18 Proportion with genital warts % 16 14 73% decrease 12 in genital warts 10 8 6 4 2 0 Half year Resident women
Tdap MCV4 >1 dose HPV (girls) 3 doses HPV (girls)
Washington Montana North Minnesota Maine Dakota V e rm ont Oregon Idaho N e w H a m ps hire South Wisconsin Massachusetts Dakota New York Wyoming Michigan Connecticut Rhode Island Iowa Pennsylvania Nevada Nebraska New Jersey Ohio Illinois Indiana Delaware Maryland Utah West Colorado California Virginia Kansas Virginia Missouri Kentucky North Carolina Tennessee Oklahoma Arkansas Arizona South New Mexico Carolina Georgia Mississippi Alabama Alaska Alaska Texas Louisiana Hawaii Florida
** **
** ** **
** Percent
Response categories are not mutually exclusive
Among girls unvaccinated for HPV, 78% had a missed opportunity
3-dose series 1 dose 1 st dose booster Annual immunization
55
57
59
Percent
65
*p<0.05 Vaccine
67
68
69
80% of cervical cancer deaths occur in developing countries Age-standardized incidence (per 100 000 women/year) 42 to 60 (12) 39 to 42 (4) 36 to 39 (4) 33 to 36 (9) 30 to 33 (6) 27 to 30 (14) 24 to 27 (9) 21 to 24 (12) 18 to 21 (12) 15 to 18 (20) 12 to 15 (16) 9 to 12 (19) 6 to 9 (23) 3 to 6 (16) 0 to 3 (6)
No (150 countries or 77%) Yes (40 countries or 21%) Yes (Part of the country) (4 countries or 2%)
Accessible version: https://youtu.be/lggKTa_C-_Q
Accessible version: https://youtu.be/RON5u27OGPM
Accessible version: https://youtu.be/Bc0qkmgWWmY
THE GROWING THREAT OF MULTIDRUG-RESISTANT GONORRHEA Accessible version:
RABIES: A NEGLECTED, RE-EMERGING ZOONOSIS Accessible version:
PUBLIC HEALTH GRAND ROUNDS Accessible version: https://youtu.be/-zryKuf7-kI
Accessible version: https://youtu.be/CZuknY8D2-A
CDC PUBLIC HEALTH GRAND ROUNDS Global Prevention of Neural Tube Defects
CDC PUBLIC HEALTH GRAND ROUNDS Time for Public Health Action on Infertility
CDC PUBLIC HEALTH GRAND ROUNDS Emerging Tickborne Diseases A Accessible
Novan Announces Presentation of Anti- Viral Data at International
CASE PRESENTATION Khuloud Abu Qasida The Royal Hospital Muscat, Sultanate of
Aim I can explain how water and nutrients are transported within the body.
Sarcoptes, Otodectes & Demodex Dr Lee Strapp BVetMed MRCVS Veterinary
Hemorrhoid & Varicose Veins Cream What is it? HemoZel Cream is a potent
Intestinal Obstruction Clinical Presentation & Causes V
VITTAIL Ltd. T V De v eloping No v el Sol ut ion s To T r ea t H u man
Surgery for Crohns and Colitis Lauren Wilson, MD Assistant Professor of
Beyond PARP - Next Generation DDR Therapeutics Q2 2017 Safe Harbor Statement
Michigan STS Data Managers Meeting August 11, 2016 Boyne Mountain Resort Up
I Always Treat Aggressively .if t here is an anat omically favorable
Aortic Valve Disease and TAVI Educational material for Staff Normal Heart